Protein synthesis inhibitor omacetaxine is effective against hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the sixth most common and the fourth most deadly cancer worldwide. The development cost of new therapeutics is a major limitation in patient outcomes. Importantly, there is a paucity of preclinical HCC models in which to test new small molecules. Herein, we implemen...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ling, Halpert, Gilad, Lerner, Michael G., Hu, Haijie, Dimitrion, Peter, Weiss, Matthew J., He, Jin, Philosophe, Benjamin, Burkhart, Richard, Burns, William R., Wesson, Russell N., MacGregor Cameron, Andrew, Wolfgang, Christopher L., Georgiades, Christos, Kawamoto, Satomi, Azad, Nilofer S., Yarchoan, Mark, Meltzer, Stephen J., Oshima, Kiyoko, Ensign, Laura M., Bader, Joel S., Selaru, Florin M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262474/
https://www.ncbi.nlm.nih.gov/pubmed/34003798
http://dx.doi.org/10.1172/jci.insight.138197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262474/
https://www.ncbi.nlm.nih.gov/pubmed/34003798
http://dx.doi.org/10.1172/jci.insight.138197

Ejemplares similares